SCHEMBL266570

SCHEMBL266570

CC(O)CN(Cc1cccc(C(=O)Nc2ccc(N3CCCCC3)cc2C(=O)NN)c1)CC(C)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
HDAC1 Q13547 1/20 0.39
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
SERPINE1 P05121 2/20 0.39
PKM P14618 2/20 0.39
QSOX1 O00391 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
ACHE P22303 1/20 0.38
TSHR P16473 3/20 0.38
TP53 P04637 2/20 0.38
RECQL P46063 1/20 0.38
PARP1 P09874 1/20 0.38
MAPK1 P28482 2/20 0.38
USP2 O75604 1/20 0.38
ESR2 Q92731 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265916 0.88 NPC1 (0.42) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL267020 0.86 F10 (0.47) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL267726 0.83 ACHE (0.41) NPC1RAB9AKMT2AMEN1HDAC1
SCHEMBL269954 0.83 MAPT (0.44) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL269955 0.83 MAPT (0.44) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL266264 0.81 ABCB1 (0.49) RAB9ASMN1; SMN2TSHRMAPK1
SCHEMBL268692 0.80 SLC34A2 (0.47) HDAC1ALDH1A1
SCHEMBL10261251 0.80 SLC34A2 (0.47) HDAC1ALDH1A1
SCHEMBL268691 0.80 SLC34A2 (0.47) HDAC1ALDH1A1
SCHEMBL268546 0.80 TSHR (0.44) NPC1RAB9AKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 NPC1 102/4885RAB9A 883/4885KMT2A 4564/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 NPC1 115/4885RAB9A 1362/4885KMT2A 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.